• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Canopus BioPharma Incorporated - Product Pipeline Review - Q4 2010 - Product Image

Canopus BioPharma Incorporated - Product Pipeline Review - Q4 2010

  • ID: 1446810
  • November 2010
  • 25 pages
  • Global Markets Direct

Canopus BioPharma Incorporated – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Canopus BioPharma Incorporated - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Canopus BioPharma Incorporated - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Canopus BioPharma Incorporated human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >



List of Tables
List of Figures
Canopus BioPharma Incorporated Snapshot
Canopus BioPharma Incorporated Overview
Key Information
Key Facts
Canopus BioPharma Incorporated – Research and Development Overview
Key Therapeutic Areas
Canopus BioPharma Incorporated – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Canopus BioPharma Incorporated – Pipeline Products Glance
Canopus BioPharma Incorporated Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Canopus BioPharma Incorporated–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Canopus BioPharma Incorporated – Drug Profiles
CB1400
Product Description
Mechanism of Action
R&D Progress
CB5300
Product Description
Mechanism of Action
R&D Progress
CB700
Product Description
Mechanism of Action
R&D Progress
CB1400
Product Description
Mechanism of Action
R&D Progress
CB5300
Product Description
Mechanism of Action
R&D Progress
Zofroxia
Product Description
Mechanism of Action
R&D Progress
Canopus BioPharma Incorporated – Pipeline Analysis
Canopus BioPharma Incorporated – Pipeline Products by Therapeutic Class
Canopus BioPharma Incorporated – Pipeline Products by Route of Administration
Canopus BioPharma Incorporated - Dormant Projects
Canopus BioPharma Incorporated – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 05, 2008: Canopus BioPharma Announces Phase II Human Clinical Trial For Innovative Hepatitis C Drug, CB5300
Sep 19, 2007: New Hepatitis C Antiviral CB5300 Identified by Canopus BioPharma Researchers to Enter Clinical Trial Assessment
Jun 23, 2006: CB1400 Enters Phase II Clinical Trials For The Prevention Of Mucositis In Patients With Cancer Of The Head And Neck
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS